GlassScriptPhysician profile
Marshall Keilson
NPI 1528068954
$8,427.80
in general payments reported to CMS, 2019-2025
49 companies · $1,037 in 2025
The $1,037 reported for 2025 was more than what 85% of Neuromusculoskeletal Medicine, Sports Medicine providers received nationally (typical 2025 total: $125).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,708 · 2020: $731 · 2021: $1,596 · 2022: $1,588 · 2023: $961 · 2024: $808 · 2025: $1,037.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,806.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,805.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,030.50 | 2019-2025 | |
| Celgene Corporation | $719.59 | 2019-2025 | Zeposia |
| Biogen, INC. | $686.46 | 2019-2025 | Vumerity, Leqembi, Tysabri |
| Abbvie INC. | $543.63 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $373.78 | 2019-2022 | |
| Eisai INC. | $370.03 | 2019-2025 | |
| Genentech USA, INC. | $291.53 | 2019-2025 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Amgen INC. | $266.97 | 2019-2025 | Uplizna |
| Tg Therapeutics, INC. | $257.05 | 2023-2025 | |
| Genzyme Corporation | $255.47 | 2019-2022 | |
| Sk Life Science, INC. | $237.14 | 2020-2025 | |
| Pfizer INC. | $231.60 | 2023-2025 | |
| Emd Serono, INC. | $216.79 | 2019-2025 | |
| Acorda Therapeutics, INC | $214.62 | 2019-2024 | Ampyra, Inbrija |
| Neurelis, INC. | $205.23 | 2020-2025 | Valtoco |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marshall Keilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.